204 related articles for article (PubMed ID: 32576963)
41. Loss of the INI1 tumor suppressor does not impair the expression of multiple BRG1-dependent genes or the assembly of SWI/SNF enzymes.
Doan DN; Veal TM; Yan Z; Wang W; Jones SN; Imbalzano AN
Oncogene; 2004 Apr; 23(19):3462-73. PubMed ID: 14990991
[TBL] [Abstract][Full Text] [Related]
42. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
43. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.
Cattoretti G; Mandelbaum J; Lee N; Chaves AH; Mahler AM; Chadburn A; Dalla-Favera R; Pasqualucci L; MacLennan AJ
Cancer Res; 2009 Nov; 69(22):8686-92. PubMed ID: 19903857
[TBL] [Abstract][Full Text] [Related]
44. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
[TBL] [Abstract][Full Text] [Related]
45. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
46. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.
Pfister NT; Fomin V; Regunath K; Zhou JY; Zhou W; Silwal-Pandit L; Freed-Pastor WA; Laptenko O; Neo SP; Bargonetti J; Hoque M; Tian B; Gunaratne J; Engebraaten O; Manley JL; Børresen-Dale AL; Neilsen PM; Prives C
Genes Dev; 2015 Jun; 29(12):1298-315. PubMed ID: 26080815
[TBL] [Abstract][Full Text] [Related]
47. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.
Alpsoy A; Dykhuizen EC
J Biol Chem; 2018 Mar; 293(11):3892-3903. PubMed ID: 29374058
[TBL] [Abstract][Full Text] [Related]
48. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.
Mandelbaum J; Bhagat G; Tang H; Mo T; Brahmachary M; Shen Q; Chadburn A; Rajewsky K; Tarakhovsky A; Pasqualucci L; Dalla-Favera R
Cancer Cell; 2010 Dec; 18(6):568-79. PubMed ID: 21156281
[TBL] [Abstract][Full Text] [Related]
49. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription.
Lee D; Kim JW; Seo T; Hwang SG; Choi EJ; Choe J
J Biol Chem; 2002 Jun; 277(25):22330-7. PubMed ID: 11950834
[TBL] [Abstract][Full Text] [Related]
50. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
51. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
52. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
53. In silico screening of cancer-associated mutations in the HSA domain of BRG1 and its role in affecting the Arp-HSA sub-complex of SWI/SNF.
S AS; Goutham R N A; Mohan S S
Comput Biol Chem; 2018 Dec; 77():109-115. PubMed ID: 30286321
[TBL] [Abstract][Full Text] [Related]
54. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
55. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
[TBL] [Abstract][Full Text] [Related]
56.
García-Ramírez I; Tadros S; González-Herrero I; Martín-Lorenzo A; Rodríguez-Hernández G; Moore D; Ruiz-Roca L; Blanco O; Alonso-López D; Rivas JL; Hartert K; Duval R; Klinkebiel D; Bast M; Vose J; Lunning M; Fu K; Greiner T; Rodrigues-Lima F; Jiménez R; Criado FJG; Cenador MBG; Brindle P; Vicente-Dueñas C; Alizadeh A; Sánchez-García I; Green MR
Blood; 2017 May; 129(19):2645-2656. PubMed ID: 28288979
[TBL] [Abstract][Full Text] [Related]
57. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
Lohr JG; Stojanov P; Lawrence MS; Auclair D; Chapuy B; Sougnez C; Cruz-Gordillo P; Knoechel B; Asmann YW; Slager SL; Novak AJ; Dogan A; Ansell SM; Link BK; Zou L; Gould J; Saksena G; Stransky N; Rangel-Escareño C; Fernandez-Lopez JC; Hidalgo-Miranda A; Melendez-Zajgla J; Hernández-Lemus E; Schwarz-Cruz y Celis A; Imaz-Rosshandler I; Ojesina AI; Jung J; Pedamallu CS; Lander ES; Habermann TM; Cerhan JR; Shipp MA; Getz G; Golub TR
Proc Natl Acad Sci U S A; 2012 Mar; 109(10):3879-84. PubMed ID: 22343534
[TBL] [Abstract][Full Text] [Related]
58. Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.
Orlando KA; Nguyen V; Raab JR; Walhart T; Weissman BE
Expert Rev Anticancer Ther; 2019 May; 19(5):375-391. PubMed ID: 30986130
[TBL] [Abstract][Full Text] [Related]
59. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
Pascual M; Mena-Varas M; Robles EF; Garcia-Barchino MJ; Panizo C; Hervas-Stubbs S; Alignani D; Sagardoy A; Martinez-Ferrandis JI; Bunting KL; Meier S; Sagaert X; Bagnara D; Guruceaga E; Blanco O; Celay J; Martínez-Baztan A; Casares N; Lasarte JJ; MacCarthy T; Melnick A; Martinez-Climent JA; Roa S
Blood; 2019 May; 133(22):2401-2412. PubMed ID: 30975638
[TBL] [Abstract][Full Text] [Related]
60. Early-Stage Induction of SWI/SNF Mutations during Esophageal Squamous Cell Carcinogenesis.
Nakazato H; Takeshima H; Kishino T; Kubo E; Hattori N; Nakajima T; Yamashita S; Igaki H; Tachimori Y; Kuniyoshi Y; Ushijima T
PLoS One; 2016; 11(1):e0147372. PubMed ID: 26812616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
